In September 2022, Roche acquired Good Therapeutics for an upfront payment of $250 million, and has access to their PD-1-regulated IL-2 program
It helps preserve the Peptide solution for a longer period
Several different brands are available, including Wegovy, Rybelsus and Mounjaro
The patient reported no family history of neurofibromatosis type 1 or 2 (NF1/NF2)
Consequences of Wegovy being backordered Because Wegovy was in short supply, patients already taking Wegovy werent able to move to the next higher dose as planned, which led to stalled progress
The most common concern is additive gastrointestinal effects, as both medications can cause nausea, with Wegovy also causing vomiting, diarrhoea, and constipation